Tau and p-tau as CSF biomarkers in dementia: a meta-analysis (Q37845820)

24 August 2017

0 references

1 reference

title

Tau and p-tau as CSF biomarkers in dementia: a meta-analysis (English)

1 reference

24 August 2017

0 references

0 references

0 references

Marinus A Blankenstein

4

0 references

Wiesje van der Flier

object named as

Wiesje M van der Flier

6

0 references

Philip Scheltens

7

object named as

Philip Scheltens

1 reference

PubMed ID

21342021

24 August 2017

Yolande A L Pijnenburg

5

object named as

Yolande A L Pijnenburg

1 reference

24 August 2017

3

Pieter-Jelle Visser

1 reference

24 August 2017

1

Argonde C van Harten

1 reference

24 August 2017

2

Maartje I Kester

1 reference

24 August 2017

23 February 2011

1 reference

Clinical Chemistry and Laboratory Medicine

24 August 2017

1 reference

24 August 2017

49

1 reference

24 August 2017

3

1 reference

24 August 2017

353-366

1 reference

Epidemiology and risk factors of dementia

24 August 2017

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Formation and development of Lewy pathology: a critical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Human transmissible spongiform encephalopathies in eleven countries: diagnostic pattern across time, 1993-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Creutzfeldt-Jakob disease: Patterns of worldwide occurrence and the significance of familial and sporadic clustering

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Total and phosphorylated tau protein as biological markers of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Pattern of Tau forms in CSF is altered in progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Neuropsychological and behavioural correlates of CSF biomarkers in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Real-time quantification of microRNAs by stem-loop RT-PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

CSF neurofilament proteins in the differential diagnosis of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Tau protein in cerebrospinal fluid from semantic dementia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

CSF biomarkers in frontotemporal lobar degeneration with known pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Both total and phosphorylated tau are increased in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Frontal lobe degeneration of non-Alzheimer type. II. Clinical picture and differential diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Biomarkers for early detection of Alzheimer pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Decreased Cerebrospinal Fluid Acetylcholinesterase in Patients with Subcortical Ischemic Vascular Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer's disease and vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid tissue transglutaminase as a biochemical marker for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Evaluation of CSF-Chlamydia pneumoniae, CSF-tau, and CSF-Abeta42 in Alzheimer's disease and vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

CSF biomarker profile and diagnostic value in vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Differential diagnosis of 201 possible Creutzfeldt-Jakob disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid markers in Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Raised CSF phospho-tau concentrations in variant Creutzfeldt-Jakob disease: diagnostic and pathological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

The role of cerebrospinal fluid proteins as early diagnostic markers for sporadic Creutzfeldt-Jakob disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Follow-up investigations of tau protein and S-100B levels in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Tau Protein in Cerebrospinal Fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldtâ Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.086

21 January 2018

Identifiers

DOI

10.1515/CCLM.2011.086

1 reference

24 August 2017

1 reference

PubMed ID

21342021